β-Cell Mass and Type 1 Diabetes: Going, Going, Gone?

Diabetes

Volumn 57, Issue 11, 2008, Pages 2883-2888

  Akirav, Eitan ^a   Kushner, Jake A ^b   Herold, Kevan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIGEN; AUTOANTIGEN; BROXURIDINE; C PEPTIDE; CD94 ANTIGEN; CHLORDANE; CYTOKINE; DIPHTHERIA TOXIN; EXENDIN 4; GLUCOSE; GLUCOSE TRANSPORTER 2; GLUTAMATE DECARBOXYLASE 65; GRANZYME; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INSULIN; INTERLEUKIN 15 IMMUNOGLOBULIN; INTERLEUKIN 1BETA; INTERLEUKIN 2 IMMUNOGLOBULIN; ISLET SPECIFIC GLUCOSE 6 PHOSPHATASE CATALYTIC SUBUNIT RELATED PROTEIN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY CD3; PROINSULIN; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGENICITY; AREA UNDER THE CURVE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CELL FUNCTION; CELL REGENERATION; CELL VOLUME; CLONOGENESIS; COXSACKIE VIRUS B4; DEGRANULATION; DIABETIC KETOACIDOSIS; DISEASE COURSE; EPITOPE MAPPING; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULITIS; LYMPH NODE; LYMPHOCYTE CLONE; NATURAL KILLER CELL; NONHUMAN; NONOBESE DIABETIC MOUSE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; REVIEW; SCID MOUSE; STEM CELL; VIRUS INFECTION; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; PATHOLOGY;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; INSULIN-SECRETING CELLS; MICE; MODELS, BIOLOGICAL;

EID: 58149348476     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1817     Document Type: Review

References (54)

1. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS: Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 48:989-996, 1999
2. Sherry NA, Tsai EB, Herold KC: Natural history of β-cell function in type 1 diabetes. Diabetes 54 (Suppl. 1):S25-S31, 2005
3. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS: Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 29:643-649, 2006
4. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS: Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 30:38-42, 2007
5. Tsai EB, Sherry NA, Palmer JP, Herold KC: The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 49:261-270, 2006
6. von Herrath M, Sanda S, Herold K: Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 7:988-994, 2007
7. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC: Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 55:3238-3245, 2006
8. Nir T, Melton DA, Dor Y: Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117:2553-2561, 2007
9. Dor Y, Brown J, Martinez OI, Melton DA: Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41-46, 2004
10. Brennand K, Huangfu D, Melton D: All beta cells contribute equally to islet growth and maintenance. PLoS Biol 5:e163, 2007
11. Teta M, Rankin MM, Long SY, Stein GM, Kushner JA: Growth and regeneration of adult beta cells does not involve specialized progenitors. Dev Cell 12:817-826, 2007
12. Butler AE, Galasso R, Meier JJ, Basu R, Rizza RA, Butler PC: Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis. Diabetologia 50:2323-2331, 2007
13. In't Veld P, Lievens D, De Grijse J, Ling Z, Van der Auwera B, Pipeleers- Marichal M, Gorus F, Pipeleers D: Screening for insulitis in adult autoan- tibody-positive organ donors. Diabetes 56:2400-2404, 2007
14. Delovitch TL, Singh B: The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7:727-738, 1997
15. Imagawa A, Hanafusa T, Tamura S, Moriwaki M, Itoh N, Yamamoto K, Iwahashi H, Yamagata K, Waguri M, Nanmo T, Uno S, Nakajima H, Namba M, Kawata S, Miyagawa JI, Matsuzawa Y: Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes 50:1269-1273, 2001
16. Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K, Waguri M, Imagawa A, Tamura S, Inada M, et al.: Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92:2313-2322, 1993
17. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P: Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 406:739-742, 2000
18. Katz JD, Benoist C, Mathis D: T helper cell subsets in insulin-dependent diabetes. Science 268:1185-1188, 1995
19. Eizirik DL, Darville MI: Beta-cell apoptosis and defense mechanisms: lessons from type 1 diabetes. Diabetes 50 (Suppl. 1):S64-S69, 2001
20. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL: Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 (Suppl. 2):S97-S107, 2005
21. Campbell IL, Kay TW, Oxbrow L, Harrison LC: Essential role for interferon- gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 87:739-742, 1991
22. Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, Colman PG, Harrison LC, Lew AM, Thomas HE, Kay TW: Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 116:3258-3265, 2006
23. O'Sullivan BJ, Thomas HE, Pai S, Santamaria P, Iwakura Y, Steptoe RJ, Kay TW, Thomas R: IL-1 beta breaks tolerance through expansion of CD25 + effector T cells. J Immunol 176:7278-7287, 2006
24. Thomas HE, Irawaty W, Darwiche R, Brodnicki TC, Santamaria P, Allison J, Kay TW: IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes 53:113-121, 2004
25. Wang B, Andre I, Gonzalez A, Katz JD, Aguet M, Benoist C, Mathis D: Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad SciUSA94:13844-13849, 1997
26. Vukkadapu SS, Belli JM, Ishii K, Jegga AG, Hutton JJ, Aronow BJ, Katz JD: Dynamic interaction between T cell-mediated beta-cell damage and beta- cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics 21:201-211, 2005
27. Doyle HA, Zhou J, Wolff MJ, Harvey BP, Roman RM, Gee RJ, Koski RA, Mamula MJ: Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity. J Biol Chem 281:32676-32683, 2006
28. Doyle HA, Mamula MJ: Posttranslational modifications of self-antigens. Ann N Y Acad Sci 1050:1-9, 2005
29. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D: Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 189:331-339, 1999
30. Turley S, Poirot L, Hattori M, Benoist C, Mathis D: Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 198:1527-1537, 2003
31. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV: Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366:69-72, 1993
32. Zechel MA, Krawetz MD, Singh B: Epitope dominance: evidence for reciprocal determinant spreading to glutamic acid decarboxylase in non- obese diabetic mice. Immunol Rev 164:111-118, 1998
33. Gurr W, Yavari R, Wen L, Shaw M, Mora C, Christa L, Sherwin RS: A Reg family protein is overexpressed in islets from a patient with new-onset type 1 diabetes and acts as T-cell autoantigen in NOD mice. Diabetes 51:339-346, 2002
34. Gurr W, Shaw M, Li Y, Sherwin R: RegII is a beta-cell protein and autoantigen in diabetes of NOD mice. Diabetes 56:34-40, 2007
35. Ott PA, Dittrich MT, Herzog BA, Guerkov R, Gottlieb PA, Putnam AL, Durinovic-Bello I, Boehm BO, Tary-Lehmann M, Lehmann PV: T cells recognize multiple GAD65 and proinsulin epitopes in human type 1 diabetes, suggesting determinant spreading. J Clin Immunol 24:327-339, 2004
36. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS: Prime role for an 2887 insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435:220-223, 2005
37. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS: Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45:926-933, 1996
38. Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, Chase P, Klingensmith G, Erlich H, Norris J, Eisenbarth GS: Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 81:4264-4267, 1996
39. Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS: Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad SciUSA 97:1701-1706, 2000
40. Yoon JW, Austin M, Onodera T, Notkins AL: Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 300:1173-1179, 1979
41. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, Mosca F, Boggi U, Muda AO, Prato SD, Elliott JF, Covacci A, Rappuoli R, Roep BO, Marchetti P: Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA104:5115-5120, 2007
42. Caprio S, Plewe G, Diamond MP, Simonson DC, Boulware SD, Sherwin RS, Tamborlane WV: Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr 114:963-967, 1989
43. Koulmanda M, Budo E, Bonner-Weir S, Qipo A, Putheti P, Degauque N, Shi H, Fan Z, Flier JS, Auchincloss H Jr, Zheng XX, Strom TB: Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci USA104:13074-13079, 2007
44. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
45. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF: The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48:751-762, 2007
46. O'Meara NM, Sturis J, Herold KC, Ostrega DM, Polonsky KS: Alterations in the patterns of insulin secretion before and after diagnosis of IDDM. Diabetes Care 18:568-571, 1995
47. Prentki M, Nolan CJ: Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802-1812, 2006
48. Steil GM, Trivedi N, Jonas JC, Hasenkamp WM, Sharma A, Bonner-Weir S, Weir GC: Adaptation of beta-cell mass to substrate oversupply: enhanced function with normal gene expression. Am J Physiol Endocrinol Metab 280:E788-E796, 2001
49. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L: Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598-2608, 2005
50. Sherry N, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone J, Brillantes AM, Herold K: Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 mAb by enhancing recovery of beta-cells. Endocrinology 148:5136-5144, 2007
51. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276, 1999
52. Nielsen LL, Baron AD: Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 4:401-405, 2003
53. De Leon DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA: Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52:365-371, 2003
54. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082-3089, 2003